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فعالية العالج بالبيسيبانيل )OK-432( لإلزالة الغري جراحية
ألورام منطقة الرأس والرقبة التكيسية
سلسلة حاالت
ه�سام يو�سف علي ح�سن و حممد عامر ر�سوان
abstract: Head and neck masses can present in different pathologies that usually vary according to the age of the 
patient. We report five cases of benign head or neck masses occurring among patients of different ages who were 
managed at the Bahrain Defence Force Royal Medical Services Hospital, Ar-Rifaa, Bahrain, between 2005–2014. All 
of the patients were treated using the sclerotherapeutic agent OK-432. Although surgical removal is usually considered 
optimal treatment in the management of such cases, OK-432 appears to be a promising alternative.
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امللخ�ص: تظهر اأورام الراأ�ض والرقبة ب�سبب اأمرا�ض خمتلفة تختلف اأنواعها عادًة ح�سب عمر املري�ض، ن�ستعر�ض هنا خم�ض حاالت اأ�سيبت 
التابع لقوة دفاع  الطبية امللكية  الرقبة ينتمون الأعمار خمتلفة ومت عالجهم يف م�ست�سفى اخلدمات  اأو  الراأ�ض  باأورام حميدة يف منطقة 
البحرين، منطقة الرفاع، مملكة البحرين يف الفرتة من عام، 2014–2005. ومت عالج جميع احلاالت با�ستخدام الدواء املحفز للت�سلب من 
 OK-432 وبالرغم من اأن االإزالة اجلراحية تعترب االأف�سل يف عالج مثل هذه احلاالت، اإال اأن العالج الت�سلبي با�ستخدام ،OK-432 نوع
قد يوفر بدياًل منا�سبًا وناجحًا.
الكي�سي؛  املائي  الورم  الل�ساين؛  الدرقي  التكي�ض  اخلي�سومي؛  التكي�ض  اللمفاوي؛  اجلهاز  عيوب  OK-432؛  الت�سلبي؛  العالج  املفتاحية:  الكلمات 
�سل�سلةحاالت؛ البحرين.
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A mixture of  bac teria in  a  he at- attenuated form was first used to treat in-operable malignancies in 1891.1 Subsequently, 
in 1967, a Streptococcus pyogenes strain was found 
to have a positive anticancer effect.2 These experi-
ments led to the development of OK-432, a freeze-
dried product prepared from the Su strain of the group 
A Streptococcus pyogenes species. Upon exposure to 
benzylpenicillin and heat treatment, the toxin-
producing capacity of the bacterium is eliminated and 
its anticancer properties are enhanced.3 This process 
involves heating the Su strain in the presence of benzyl-
penicillin at 37 °C for 20 minutes and then 45 °C 
for 30 minutes. At this stage, the product is known as 
PC-B-45 or OK-431, before becoming OK-432 after 
being freeze-dried.3 The product contains an intact 
bacterial cell wall devoid of its toxin-producing 
properties, consequently eliminating its ability to cause 
infection and proliferate. Each dose is measured in 
Klinische Einheit (KE), of which one KE equals 0.1 mg 
of freeze-dried Streptococci containing approximately 
1 x 108 cells.3 
Cystic neck masses can be either congenital or 
acquired. Branchial cleft cysts, thyroglossal duct cysts, 
cystic lymphangiomas, dermoid cysts, ranulae and 
laryngoceles are common congenital neck masses, 
while acquired neck cysts include laryngoceles, cystic 
schwannomas and parotid cysts.4 A provisional diag- 
nosis can be made based on the age and clinical 
presentation of the patient, which can subsequently be 
confirmed using radiological and pathological investi-
gations. In general, benign cystic neck masses such as 
branchial cleft cysts, lymphangiomas and plunging 
ranulae are usually amenable to surgical excision; 
however, the lesions may recur due to the technically-
challenging nature of the surgical intervention or 
inadequate excision to avoid nerve or vessel injury.5 
Classically, residual disease and subsequent recurrence 
is more commonly encountered with lymphatic mal-
formations and branchial cystic masses.6
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Alternative non-surgical modalities—including 
cryotherapy, diathermy, radiofrequency ablation and 
laser treatment—have been employed in the treatment 
of cystic head and neck lesions, with varying degrees 
of success.7 A more appealing alternative is sclero-
therapy, including bleomycin, ethanol and sodium 
tetradecyl sulphate.8 In 1986, Ogita et al. first noted 
that OK-432 injections were effective in reducing or 
even completely resolving unresectable paediatric lymph- 
angiomas.9 Since then, OK-432 has been investigated 
to determine its potential benefits in treating head 
and neck cystic masses in both children and adults.10 
Patients who fail to respond to surgical management 
are often successfully treated with OK-432, with even 
more promising results in conjunction with surgery.11 
Overall, OK-432 has proven effective in the treatment 
of malignant ascites, pleural effusion and lymphatic 
malformations.12 This case series describes five patients 
with cystic head or neck lesions who were successfully 
treated with OK-432 therapy at the Bahrain Defence 
Force Royal Medical Services Hospital, Ar-Rifaa, 
Bahrain.
Case One
A 54-year-old woman presented in 2014 with a 
recurrent branchial cyst following a previous surgical 
excision at another hospital. Postoperatively, she had 
suffered from temporary palsy of the marginal mandib-
ular branch. At presentation, the cyst measured 3.9 x 
1.5 cm and was located in the left lateral region of the 
upper neck [Figure 1]. The patient feared undergoing 
a second, potentially more difficult surgery with an 
increased risk of complications. For this reason, intra- 
lesional OK-432 treatment was initiated. After two 
sessions, the cyst had regressed and was no longer 
visible or palpable. The patient experienced no complic- 
ations. She was followed up for two years after the treat- 
ment, with no evidence of recurrence. Unfortunately, 
longer-term follow-up was not possible as the patient 
moved abroad.
Case Two
A two-year-old male child presented in 2012 with a 
three-month history of a cyst in the left upper neck, 
measuring 5.2 x 3.5 cm [Figure 2]. The patient under-
went nine sessions of OK-432 sclerotherapy, with no 
complications, resulting in complete resolution of the 
lesion. The patient was followed up for four years with 
no evidence of recurrence.
Case Three
An eight-month-old female child presented in 2005 
with a congenital mass measuring 6.21 x 4.52 x 3.92 cm 
in the right supraclavicular fossa [Figure 3]. Clinically 
and radiologically, the mass appeared consistent with 
a cystic hygroma. Three sessions of OK-432 sclerotherapy 
resulted in the total dissolution of the cyst. The patient 
had no complications and was followed up for nine years 
with no recurrence.
Case Four 
A 30-year-old woman presented in 2011 with a five- 
month history of a midline neck swelling that moved 
upon swallowing or extension of the tongue. Computed 
tomography of the neck showed a cystic mass measuring 
2.5 x 1.5 x 2.7 cm, consistent with a thyroglossal cyst. 
 
Figure 1: Photographs of a 54-year-old woman with 
a left branchial cyst which had (A) recurred following 
surgery but (B) resolved following OK-432 treatment.
 
Figure 3: Photographs of an eight-month-old female 
child with a cystic hygroma (A) before and (B) after 
treatment with OK-432 sclerotherapy.
 
Figure 2: Photographs of a two-year-old male child with 
a left branchial cyst (A) before and (B) after treatment 
with OK-432 sclerotherapy.
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As the patient did not wish to undergo a surgery which 
might potentially cause scarring, OK-432 treatment 
was her preferred option. She completed a total of four 
sessions of OK-432 sclerotherapy uneventfully, with 
no subsequent recurrence over the next three years. 
Case Five
A 44-year-old man presented in 2013 with a left 
parotid cystic swelling that had persisted for a year. 
Ultrasound-guided fine needle aspiration cytology 
confirmed the benign nature of the cystic mass, with 
a final diagnosis of an idiopathic benign cyst. The 
patient was given a single dose of intralesional OK-432 
under ultrasound guidance and the swelling resolved 
completely without any complications.
None of the five patients demonstrated any allergic 
reactions to the treatment or untoward side-effects. 
In addition, all of the patients were compliant with the 
planned treatment and participated in each session 
as scheduled. A summary of the cases is provided in 
Table 1.
Discussion
Overall, the outcome of OK-432 treatment for 
all five patients reported in the current case series 
was positive, with no undue adverse reactions 
observed. Several previous reports have indicated 
the effectiveness of OK-432 sclerotherapy as treatment 
for a variety of cystic neck lesions, usually resulting in 
total or near complete resolution of the lesion with no 
recurrence.10–12 In their original research, Ogita et al. 
reported an overall cure rate of 91.3%.9 In the current 
case series, all five of the patients were cured as a result 
of OK-432 sclerotherapy; moreover, the treatment 
was able to resolve the postoperative recurrence of a 
branchial cyst in case one. Differences in the patients’ 
ages at the time of treatment did not seem to affect 
the efficacy of the treatment. Additionally, none of the 
patients reported any skin discoloration or local scarring 
during or after OK-432 treatment. This is consistent 
with the findings of Ohta et al.13
During embryological development, the failed 
closure of the branchial cleft can lead to the formation of 
either a branchial cyst (75%) or a sinus fistula (25%).14
In the current case series, two patients (cases one 
and two) had unilocular branchial cysts. Interestingly, 
the first case involved an adult who had previously 
undergone surgical excision and subsequent recurr-
ence of the lesion. Neither cases had residual masses 
after treatment, yielding a 100% response rate to 
OK-432 sclerotherapy alone. Kim et al. reported 
that 60.8% of patients with unilocular branchial cysts 
experienced total regression following OK-432 treat- 
ment, with no or partial response in cases of multi-
locular cysts.7 In another study, Roh et al. found that 
seven out of 12 patients with branchial cysts exper-
ienced full resolution following OK-432 treatment, 
while three patients exhibited a partial response and 
the treatment failed in two patients.15 In both of the 
aforementioned studies, patients who did not respond 
to OK-432 treatment subsequently underwent surgical 
excision, thus indicating that this may be a potential 
salvage option in such cases.7,15
Lymphatic malformations are classified into 
microcystic, macrocystic and combined types. In 
50% of cases, the malformations are present at birth, 
with another 40% emerging by the age of two years.16 
The spontaneous resolution of cystic hygromas is 
rare and occurs in less than 12.5% of cases.17 Surgical 
management is complicated by the high risk of 
injury to the surrounding neurovascular structures, 
scarring and recurrence. Various sclerotherapy agents 
have been used to treat macrocystic lymphatic mal-
formations, including alcoholic solution of zein, pure 
ethanol, bleomycin A5, doxycycline, acetic acid and 
polidocanol.18 In the third case reported in the present 
series, the patient responded well to OK-432 therapy 
with no residual mass or recurrence of the cystic 
hygroma after three doses. In their study of massive 
macrocystic lymphatic malformations, Chen et al. 
observed excellent outcomes with a combination of 
fibrin glue, OK-432 and bleomycin in 53% of patients, 
in comparison to good and partial outcomes in 33% 
and 13% of cases, respectively.19 None of the patients 
required surgical excision.19
Table 1: Summary of five cases of benign cystic head or neck masses treated with OK-432 sclerotherapy
Case Diagnosis Age in years Size in cm Number of 
treatment sessions
Outcome
1 Branchial cyst 54 3.9 x 1.5 2 Resolved
2 Branchial cyst 2 5.2 x 3.5 9 Resolved
3 Cystic hygroma 0.6 6.21 x 4.52 x 3.92 3 Resolved
4 Thyroglossal cyst 30 2.5 x 1.5 x 2.7 4 Resolved
5 Benign parotid cyst 44 6.0 x 1.4 1 Resolved
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Thyroglossal duct cysts account for 70% of 
congenital neck masses; these lesions have a bimodal 
age distribution in which 90% of patients present 
by the age of 10 years, with a second peak in young 
adulthood.4 Surgery in the form of a classic Sistrunk 
procedure is the preferred method of management.20 
Kim et al. reported reduction in the volume of the cyst 
in 81.3% of patients undergoing ethanol sclerotherapy 
ablation.21 The same authors reported that 41.4% of 
thyroglossal duct cysts treated with OK-432 showed 
complete regression.22 Ohta et al. reported that OK-432 
therapy had better results for patients with thyroglossal 
cysts compared to branchial cysts.23 However, in the 
current case series, there was complete regression in 
both cases one and four, regardless of the type of cyst. 
Cystic lesions in the parotid gland can be either 
bilateral or unilateral and congenital or acquired. 
Congenital cysts can present at birth but most 
often reveal themselves in adulthood.4 Occasionally, 
systemic diseases such as Sjögren’s syndrome and HIV 
may present with bilateral benign parotid cysts.24 While 
benign parotid cysts are usually managed surgically, 
there has been recent evidence supporting the use of 
sclerotherapy. For example, Monama et al. reported 
the complete resolution of parotid cysts without 
morbidity in three adult patients following bleomycin 
sclerotherapy.25 In the current case series, the fifth 
patient underwent aspiration of a parotid cyst under 
ultrasonic guidance in order to exclude malignancy 
before commencing OK-432 treatment. This resulted 
in complete regression with no recurrence within the 
subsequent follow-up period.
Conclusion
Sclerotherapy is the optimal therapeutic choice for 
a variety of benign cystic neck masses. The safety, 
effectiveness and economic and cosmetic advantages 
of the sclerotherapeutic agent OK-432 make this 
modality a favourable alternative to surgery in the 
management of various otolaryngological cystic head 
and neck masses, including lymphatic cystic lesions 
as well as thyroglossal duct and branchial cysts. 
Furthermore, surgery can be reserved as a salvage 
procedure following OK-432 treatment in cases of 
postsurgical recurrence or residual disease.
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